跳转至内容
Merck
CN
所有图片(3)

文件

安全信息

478M-9

Sigma-Aldrich

CDK4 (DCS-31) Mouse Monoclonal Antibody

登录查看公司和协议定价
所有图片(3)

About This Item

UNSPSC代码:
12352203

生物来源

mouse

质量水平

100
500

偶联物

unconjugated

抗体形式

culture supernatant

抗体产品类型

primary antibodies

克隆

DCS-31, monoclonal

描述

For In Vitro Diagnostic Use in Select Regions

形式

buffered aqueous solution

种属反应性

human

包装

vial of 0.1 mL concentrate (478M-94)
vial of 0.1 mL concentrate Research Use Only (478M-94-RUO)
vial of 0.5 mL concentrate (478M-95)
vial of 1.0 mL concentrate (478M-96)
vial of 1.0 mL concentrate Research Use Only (478M-96-RUO)
vial of 1.0 mL pre-dilute Research Use Only (478M-97-RUO)
vial of 1.0 mL pre-dilute ready-to-use (478M-97)
vial of 7.0 mL pre-dilute ready-to-use (478M-98)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (478M-98-RUO)

制造商/商品名称

Cell Marque™

技术

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:50 (concentrated)

同位素/亚型

IgG

控制

dedifferentiated liposarcoma, well-differentiated liposarcoma

运输

wet ice

储存温度

2-8°C

可视化

nuclear

相关类别

一般描述

Well-differentiated liposarcoma is a malignant, non-metastasizing tumor that can present with similar histological characteristics as benign lipoma lesions and has a higher recurrence rate. The CDK4 protein is frequently overexpressed in well-differentiated liposarcoma due to gene amplification of the 12q13-15 chromosomal region that harbors the CDK4 gene, but amplification and subsequent overexpression is rarely observed in lipomas. Due to CDK4 protein expression differences between these lesions, anti-CDK4 antibody can be used in an immunohistochemistry panel as an aid in the differential diagnosis between well-differentiated liposarcoma and lipoma.1,2,3

质量

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

外形

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

制备说明

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

其他说明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律信息

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Matthieu Bui Nguyen Binh et al.
The American journal of surgical pathology, 29(10), 1340-1347 (2005-09-15)
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) may be difficult to distinguish from benign adipose tumors and from poorly differentiated sarcomas, respectively. Genetically, they are characterized by amplification of MDM2 and CDK4 genes on chromosome 12q13-15. We examined
P B Aleixo et al.
Journal of clinical pathology, 62(12), 1127-1135 (2009-12-01)
Well differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) have been shown to have supernumerary chromosomes with amplified sequences of the MDM2 and CDK4 genes. MDM2 and CDK4 protein overexpression have also been identified in these tumours. To investigate whether immunohistochemistry
Khin Thway et al.
The American journal of surgical pathology, 36(3), 462-469 (2012-02-04)
Adipocytic tumors are the most common type of soft tissue neoplasms. Distinguishing atypical lipomatous tumor-well-differentiated liposarcoma (WDL) from benign adipocytic neoplasms and dedifferentiated liposarcoma (DDL) from pleomorphic or myxoid liposarcoma (LPS) can be difficult. WDL and DDL characteristically harbor amplifications

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门